GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Equity-to-Asset

Genor Biopharma Holdings (HKSE:06998) Equity-to-Asset : 0.83 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genor Biopharma Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$1,143.34 Mil. Genor Biopharma Holdings's Total Assets for the quarter that ended in Jun. 2024 was HK$1,371.86 Mil. Therefore, Genor Biopharma Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.83.

The historical rank and industry rank for Genor Biopharma Holdings's Equity-to-Asset or its related term are showing as below:

HKSE:06998' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3   Med: 0.85   Max: 0.91
Current: 0.83

During the past 6 years, the highest Equity to Asset Ratio of Genor Biopharma Holdings was 0.91. The lowest was 0.30. And the median was 0.85.

HKSE:06998's Equity-to-Asset is ranked better than
71.95% of 1508 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:06998: 0.83

Genor Biopharma Holdings Equity-to-Asset Historical Data

The historical data trend for Genor Biopharma Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Equity-to-Asset Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.30 0.91 0.87 0.85 0.82

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.87 0.85 0.85 0.82 0.83

Competitive Comparison of Genor Biopharma Holdings's Equity-to-Asset

For the Biotechnology subindustry, Genor Biopharma Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Equity-to-Asset falls into.



Genor Biopharma Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Genor Biopharma Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1300.3/1582.564
=

Genor Biopharma Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=1143.339/1371.862
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genor Biopharma Holdings  (HKSE:06998) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Genor Biopharma Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings Business Description

Traded in Other Exchanges
Address
690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Forebright New Opportunities Fund, L.p. 2101 Beneficial owner
Forbright Global Limited 2201 Interest of corporation controlled by you
Fnof Gp Limited 2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh 2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd. 2101 Beneficial owner
Hsg Holding Limited 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p. 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p. 2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital I, L.p. 2101 Beneficial owner
Ni Xin 2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines